Versartis Inc. (VSAR) 18.56 $VSAR Versartis Initiates

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 5:06 PM

Versartis Inc. (VSAR) 18.56 $VSAR

Versartis Initiates Phase 2/3 Trial of VRS-317 in Japan for Children With Growth Hormone Deficiency
GlobeNewswire - Mon Apr 13, 7:30AM CDT
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced the initiation of its Phase 2/3 study of VRS-317 in Japan for children with growth hormone deficiency (GHD).
VSAR: 18.56 (+0.17)

Versartis Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Feb 12, 4:07PM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced financial results for the fourth quarter and full year ended December 31, 2014.
VSAR: 18.56 (+0.17)

Versartis misses by $0.21
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 4:05PM CST

VSAR: 18.56 (+0.17)

Versartis to Present at the 2015 BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:05PM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced that Jeffrey L. Cleland, PhD, Chief Executive Officer, is scheduled to present at the 2015 BIO CEO & Investor Conference on Tuesday, February 10, 2015 at The Waldorf Astoria in New York City.
VSAR: 18.56 (+0.17)

InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST

STX: 58.34 (-0.41), CSWC: 47.47 (+0.10), FCS: 18.62 (-0.58), MLNK: 3.66 (-0.05), ADBE: 76.54 (+0.02), VSAR: 18.56 (+0.17), LCI: 67.40 (unch), WIW: 11.55 (+0.04), QRVO: 70.12 (-3.15), PSEM: 13.36 (-0.71), OPK: 14.83 (+0.17), CUDA: 46.12 (+0.24), BGG: 19.85 (-0.88), RWC: 6.39 (+0.04), PE: 16.72 (+0.02), MSFT: 47.87 (+4.53), BK: 42.07 (-0.51), FPRX: 24.20 (-0.26), INFN: 20.15 (+0.81)

InsiderInsights.com Daily Round Up 1/26/15: THRM, FXCM, OPK, TCBI
InsiderInsights - at Seeking Alpha - Wed Jan 28, 3:00AM CST

AZZ: 48.03 (+0.29), IGTE: 45.85 (-0.05), BALT: 1.61 (-0.04), EGBN: 37.92 (+0.80), FXCM: 2.08 (-0.03), TCBI: 51.61 (-0.61), THRM: 52.62 (+0.74), VEEV: 27.17 (-0.24), VSAR: 18.56 (+0.17), PN: 14.13 (+0.44), LNKD: 260.95 (+4.71), OPK: 14.83 (+0.17), NERV: 5.74 (+0.15), CAS: 3.70 (-0.04), SGNT: 25.20 (-0.40), ARIA: 9.71 (+0.10), TWTR: 50.82 (-0.59), BKE: 47.70 (unch)

Versartis prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:32AM CST

VSAR: 18.56 (+0.17)

Versartis Announces Pricing of Follow-On Offering
GlobeNewswire - Wed Jan 21, 7:44PM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced the pricing of an underwritten public offering of 4,347,826 shares of its common stock at a price to the public of $17.25 per share. In addition, Versartis has granted the underwriters a 30-day option to purchase up to 652,173 additional shares of common stock. The offering is expected to close on January 27, 2015, subject to customary closing conditions.
VSAR: 18.56 (+0.17)

Nasdaq stocks posting largest percentage decreases
AP - Wed Jan 21, 5:01PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VSAR: 18.56 (+0.17), IMDZ: 26.56 (-0.42), ADXS: 23.34 (-0.27), ALDX: 9.56 (-0.18), ACTG: 11.10 (+1.08), BONT: 7.35 (+0.19), IMKTA: 47.61 (+0.33), AAVL: 37.57 (-0.92), OUTR: 70.38 (+0.12)

Versartis Announces Proposed Offering of Common Stock
GlobeNewswire - Tue Jan 20, 5:10AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $75,000,000. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the shares in the offering will be sold by Versartis.
VSAR: 18.56 (+0.17)

Versartis Initiates Global Phase 3 Study of VRS-317 in Children With Growth Hormone Deficiency
GlobeNewswire - Thu Jan 08, 7:50AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced the initiation of its Phase 3 study of VRS-317 for semi-monthly dosing in children with growth hormone deficiency (GHD). This registration trial follows positive data from the Company's completed Phase 1b/2a VERTICAL study and the ongoing long-term Extension Study.
VSAR: 18.56 (+0.17)

Versartis Announces Positive 12 Month Data for VRS-317 from Ongoing Extension Study
PR Newswire - Mon Jan 05, 7:00AM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced positive data from its Extension Study of VRS-317 for naive to treatment, pre-pubertal children with growth hormone deficiency (GHD). The Extension Study is a long-term safety study initiated in March 2014 as patients completed the Versartis' Phase 1b/2a clinical trial of VRS-317 in children with GHD.
VSAR: 18.56 (+0.17)

Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study
GlobeNewswire - Mon Dec 29, 7:36AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Monday, January 5, 2015 at 8:30 a.m. ET (5:30 a.m. PT).
VSAR: 18.56 (+0.17)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 40.03 (-0.67), ZSPH: 40.97 (-1.90), AMRN: 2.33 (-0.10), OPHT: 52.15 (+0.17), AERI: 12.87 (-22.52), ASPX: 100.88 (-0.01), CNCE: 14.68 (-0.26), ICEL: 16.48 (-0.02), GWPH: 121.00 (+0.23), AUXL: 36.47 (-0.06), RTRX: 24.75 (+0.01), RCPT: 169.88 (-1.26), AAVL: 37.57 (-0.92), AKBA: 8.67 (-0.08), EXPR: 17.59 (+0.17), RARE: 69.65 (+0.75), RLYP: 34.83 (-0.64), PETX: 15.86 (-0.43), ENTA: 37.14 (+0.56), RDUS: 41.01 (-0.95), CARA: 12.71 (-0.15), FLML: 15.88 (+0.02), ALIM: 4.94 (-0.07), ANIP: 70.26 (-1.52), ICPT: 283.20 (-2.22), RVNC: 21.92 (-0.12), POZN: 8.40 (+0.08), FPRX: 24.20 (-0.26), ZFGN: 39.90 (-0.62), CRIS: 2.96 (-0.01), QLTI: 3.70 (-0.02), PCYC: 256.59 (-0.51), PTX: 7.09 (-0.24), CLDN: 13.68 (-0.26), RIGL: 4.88 (+0.55), HPTX: 45.97 (-0.11), AMPH: 15.25 (-0.04), INO: 10.35 (-0.25), VSAR: 18.56 (+0.17), FMI: 46.57 (-2.16), TBPH: 18.39 (+0.06), XLRN: 33.29 (-0.95), MGNX: 33.96 (+0.09), INSM: 23.25 (-0.21), ONTX: 2.34 (-0.05), ALDR: 25.10 (-0.25), SAGE: 58.57 (-1.37), KITE: 60.58 (-0.35), CGEN: 7.00 (-0.09), FOLD: 12.25 (-0.05), KPTI: 31.49 (-1.13)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 40.03 (-0.67), ZSPH: 40.97 (-1.90), AMRN: 2.33 (-0.10), OPHT: 52.15 (+0.17), AERI: 12.87 (-22.52), ASPX: 100.88 (-0.01), CNCE: 14.68 (-0.26), ICEL: 16.48 (-0.02), GWPH: 121.00 (+0.23), AUXL: 36.47 (-0.06), RTRX: 24.75 (+0.01), RCPT: 169.88 (-1.26), AAVL: 37.57 (-0.92), AKBA: 8.67 (-0.08), EXPR: 17.59 (+0.17), RARE: 69.65 (+0.75), ZGNX: 1.54 (-0.11), RLYP: 34.83 (-0.64), PETX: 15.86 (-0.43), ENTA: 37.14 (+0.56), RDUS: 41.01 (-0.95), CARA: 12.71 (-0.15), FLML: 15.88 (+0.02), ALIM: 4.94 (-0.07), ANIP: 70.26 (-1.52), ICPT: 283.20 (-2.22), RVNC: 21.92 (-0.12), POZN: 8.40 (+0.08), NDAQ: 48.57 (-1.19), FPRX: 24.20 (-0.26), CRIS: 2.96 (-0.01), ZFGN: 39.90 (-0.62), QLTI: 3.70 (-0.02), PCYC: 256.59 (-0.51), PTX: 7.09 (-0.24), CLDN: 13.68 (-0.26), RIGL: 4.88 (+0.55), HPTX: 45.97 (-0.11), AMPH: 15.25 (-0.04), INO: 10.35 (-0.25), VSAR: 18.56 (+0.17), FMI: 46.57 (-2.16), TBPH: 18.39 (+0.06), XLRN: 33.29 (-0.95), MGNX: 33.96 (+0.09), INSM: 23.25 (-0.21), ONTX: 2.34 (-0.05), ALDR: 25.10 (-0.25), SAGE: 58.57 (-1.37), KITE: 60.58 (-0.35), CGEN: 7.00 (-0.09), FOLD: 12.25 (-0.05), KPTI: 31.49 (-1.13)

InsiderInsights.com Daily Round Up 11/20/14: NES, OPK, OKS, PAH
InsiderInsights - at Seeking Alpha - Mon Nov 24, 2:04PM CST

NES: 3.80 (-0.07), RAX: 54.64 (+1.64), JAH: 52.23 (-0.97), LNG: 77.29 (-1.35), MRD: 19.33 (+0.12), PAH: 27.18 (-0.76), AON: 97.84 (+0.43), SGM: 11.01 (-0.24), CLI: 18.68 (-0.03), CNCE: 14.68 (-0.26), VSAR: 18.56 (+0.17), OPK: 14.83 (+0.17), HZNP: 31.75 (+0.97), CATY: 28.73 (-0.24), IMH: 19.20 (+4.78), OKS: 42.05 (-0.02), GRPN: 7.11 (-0.04), SFXE: 4.46 (-0.04), SCHW: 30.12 (-0.38)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI in Music: CITY JAM Focuses on Human Creativity

Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...

Haag-Streit Debuts Innovative Octopus 910 Perimeter at AAO

Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...

tm:rw Revolutionizes Retail with Live TikTok Studios

tm:rw Takes a Bold Step into Social Commerce Throw out whatever you've thought about traditional brick-and-mortar retail because tm:rw isn't just bending the rules—it's burning the book. Launching nine branded studio spaces at their Times Square flagship, tm:rw is blending live streaming with in-person shopping, all in sync with TikTok Shop. The experience is less about...

Tchah Sup Kim: A Retrospective at KCCNY in 2026

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...

Retail Trading Platforms Report Record Growth in 2026

A Boom in Self-Directed Investing Times are changing, folks. More people than ever are taking finance into their own hands, wielding smartphones like fiscal swords in the name of self-directed investment. No middlemen, no fancy office, just straight-up trading from wherever you might be perched. Four major platforms now boast over 41 million funded accounts combined, each...

Amap, Sands China Unleash Tutu Robots for Resort Duty

Tutu Robots Usher in a New Technological Era for Sands China Alright, let's dive into some tech that feels out of a sci-fi movie and see what Sands China and Amap have cooked up as they introduce the Tutu robot dogs to Sands Resorts Macau. These aren't your run-of-the-mill gadgets—they're futuristic tour guides ready to rewire visitor experiences. The delivery ceremony...

RingConn Smart Ring Gains Key FDA 510(k) Clearance

FDA Clearance: A Major Step for RingConn In a space where every tiny gadget-maker is desperately clawing for a regulatory nod, RingConn—a venture born from Shenzhen Ninenovo Technology Limited—has snagged an FDA 510(k) clearance (Clearance No. K260490) for their wearable Smart Ring that measures blood oxygen levels non-invasively. October 10, 2026, marked the day when...

New Docs Spotlight Psychiatry on World Mental Health Day

Unmasking Mental Health on the Global Stage Hold onto your hats, folks. The Scientology Network is cranking up the heat this World Mental Health Day. On October 10, they’re rolling out a program that puts the spotlight on CCHR’s crusade against what they see as dark forces in the psychiatric industry. It’s a marathon of documentaries that dives into allegations of...

Jiangxi Dialogues: Youths Forge Global Ties in 2026

Bringing Global Youth to the Table In the heart of Jiangxi, China, young minds from across the globe gathered not just to chat but to shape the future. A bunch who only a decade ago might have been ignored in such circles are now leading discussions, and they’ve kicked off their powwow on September 22, 2026, with a bang in Nanchang. What’s the Agenda? Imagine more...

Arrvel's Thermal Printers: Aiming at E-Com Sellers

Arrvel's Thermal Printing Push: An Overview No one would have pegged tiny thermal label printers as game-changers, but here we are. Arrvel's new lineup of thermal printers is shaking up the world for anyone who's ever had to slap on a shipping label or get inventory organized. They're targeting e-commerce folks and small businesses, which sounds like the right move as...